Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan On-Demand for Episodic Heartburn in NERD (NERD-201)
NCT04799158Phase 2Completed
- Sponsor
- Phathom Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vonoprazan in Non-erosive Gastroesophageal Reflux Disease (NERD) (5 arms), sponsored by Phathom Pharmaceuticals. Primary endpoint: Percentage of Evaluable Heartburn Episodes Completely Relieved Within 3 Hours and With No Further Heartburn Reported for 24 Hours After Taking Study Drug. Started Mar 2021; status: completed.
02
Drugs
vonoprazan
03
Conditions
Non-erosive Gastroesophageal Reflux Disease (NERD)
Beyond the preview
Go deeper on NCT04799158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04799158.